Deepak Nitrite Ltd P/E Ratio

The P/E Ratio of Deepak Nitrite Ltd is 54.7 as of 26 Jul 9.00 AM .a1#The P/E Ratio of Deepak Nitrite Ltd changed from 21.6 on March 2019 to 35.7 on March 2024 . This represents a CAGR of 8.73% over 6 years. a1#The Latest Trading Price of Deepak Nitrite Ltd is ₹ 2920 as of 26 Jul 15:30 .a1#The PE Ratio of Chemicals Industry has changed from 18.4 to 26.3 in 5 years. This represents a CAGR of 7.41%a1# The PE Ratio of Automobile industry is 18.9. The PE Ratio of Chemicals industry is 58.1. The PE Ratio of Finance industry is 23.0. The PE Ratio of IT - Software industry is 29.1. The PE Ratio of Retail industry is 143.1. The PE Ratio of Textiles industry is 24.3. In 2024a1#The Market Cap of Deepak Nitrite Ltd changed from ₹ 3745 crore on March 2019 to ₹ 28937 crore on March 2024 . This represents a CAGR of 40.60% over 6 years. a1#The Revenue of Deepak Nitrite Ltd changed from ₹ 2067 crore to ₹ 2225 crore over 8 quarters. This represents a CAGR of 3.74% a1#The EBITDA of Deepak Nitrite Ltd changed from ₹ 365.59 crore to ₹ 400.06 crore over 8 quarters. This represents a CAGR of 4.61% a1#The Net Pr of Deepak Nitrite Ltd changed from ₹ 234.62 crore to ₹ 253.85 crore over 8 quarters. This represents a CAGR of 4.02% a1#The Dividend Payout of Deepak Nitrite Ltd changed from 19.76 % on March 2019 to 23.6 % on March 2024 . This represents a CAGR of 3.00% over 6 years. a1#

Its manufacturing facilities are located at Nandesari and Dahej in Gujarat, Roha and Taloja in Maharashtra, and Hyderabad in Telengana. During the year the 1984-1985, the company started to manufacture 3000 TPA concentrated nitric acid and in the same year the company commissioned its hexamine plant. During the year 1996-1997, the company's Taloja Chemical division established the plant for Hydrogenation of Nitromatics at Taloja and started commercial production of Toluidines. During the year 1999-2000, the company acquired 68.76 % equity capital of Aryan Pesticides Ltd (APL). The Board of Directors of Deepak Nitrite's at their meeting held on August 7, 2014 approved to undertake a Greenfield project for manufacturing Phenol and Acetone at Dahej, in the State of Gujarat. Within pharma and personal care, the company started offering multiple new drug intermediates for which it received favourable response from multinational companies. During the year under review, the company leveraged its strength to switch to enhance the volumes of value added products to mitigate impact from down-cycle of existing product categories. Towards the end of the year, there was some disruption in demand in end-user industries of certain customers as a result of the demonetisation initiative. Accordingly, 1,44,23,076 Equity Shares of Rs 2/- each were allotted to QIBs on March 7, 2017 at an issue price of Rs 104 per Equity Share (including premium of Rs 102 per Equity Share). The QIP issue proceeds aggregating to Rs 150 crores will be utilised in accordance with the objects stated in the offer document.